Allergan announced the launch of the new Liletta (levonorgestrel-releasing intrauterine system) 52 mg IUD single-handed inserter (intrauterine device), for use...
Objectives: Safe and effective contraceptive options for obese women are becoming more important due to the obesity epidemic within the...
Bayer HealthCare has successfully concluded the European registration procedure for its new low dose levonorgestrel-releasing intrauterine system (IUS) called Jaydress....
Allergan has announced that the U.S. FDA has accepted for filing the company's supplemental New Drug Application (sNDA) to potentially...
Medicines360/Allergan announced newly published data finding that Liletta (levonorgestrel releasing intrauterine system) is highly efficacious in preventing pregnancy over five...
The FDA has approved a new low-dose hormone intrauterine device designed to prevent pregnancy, the first new device of its...
Medicines360 presented new six-year data from the ongoing multi-center U.S.-based pivotal clinical trial investigating its intrauterine system (IUS), Liletta (levonorgestrel-releasing...
Medicines360, a global nonprofit organization with a mission to expand women’s access to quality medicines, announced that the FDA has approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use of Liletta (levonorgestrel-releasing intrauterine system) 52 mg to prevent pregnancy for up to eight years.
Actavis and Medicines360 have announced the approval of Liletta (levonorgestrel-releasing intrauterine system) by the FDA for use by women to...
Contraception for up to 5 years.